Mitoxantrone as single agent in the treatment of advanced breast cancer: clinical experience at Siriraj Hospital.
Artigo
em Inglês
| IMSEAR
| ID: sea-43216
ABSTRACT
A total of 35 patients with advanced breast cancer were treated with mitoxantrone, 14 mg/m2 I.V. every 3 weeks. Of these, 27 patients or 78 lesions could be evaluated for response and all 35 patients for toxicity. The overall response rate (CR + PR) was 35 per cent (or CR + PR + SD = 82%), ten lesions achieved a complete response and 17 lesions a partial response. The duration of response varied from a minimum of 2 months to more than 11 months (median = 4 months). Myelosuppression was the dose-limiting toxicity with moderate to severe degree in 19 patients. The most frequent severe degree in 19 patients. The most frequent non-hematologic toxicity was mild grade of nausea and vomiting (67%). No cardiotoxicity was noted in this study after the maximum cumulative dose of mitoxantrone 157.5 mg.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Neoplasias da Mama
/
Idoso
/
Feminino
/
Humanos
/
Mitoxantrona
/
Adulto
/
Pessoa de Meia-Idade
Idioma:
Inglês
Ano de publicação:
1989
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS